GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting

Glucagon-like peptide-1 (GLP-1) receptor agonists, alongside dual receptor agonists targeting glucose-dependent insulinotropic polypeptide (GIP) receptors, represent transformative therapies for obesity management. Despite their increasing use, patient perspectives of these treatments remain underexplored. This exploratory study aimed to examine the experiences and attitudes of individuals using GLP-1 medications (GLP-1s) for weight loss, focusing on motivators, barriers and reasons for discontinuation.

Surveys were conducted to assess both the overall experience of using GLP-1s and the factors influencing discontinuation. A complementary video diary study provided qualitative insights into personal weight loss journeys.

Findings highlighted that 55% of 1659 participants had attempted weight loss for over 10 years before starting GLP-1s. Perceived barriers to weight loss included eating habits, stress and menopause. Motivators centered on reducing weight-related health risks and improving body satisfaction. Discontinuation was influenced by treatment costs, unmet weight loss expectations and side effects. Participants reported that GLP-1 medications effectively reduced food-related thoughts ('food noise'), improved satiety and supported healthier eating behaviours. However, stigma and affordability challenges were notable deterrents. While some patients adopted lifestyle changes alongside the treatment, others relied predominantly on GLP-1s for results.

These findings underscore the importance of addressing patient-specific motivators and barriers during consultations to optimise outcomes and ensure sustainable weight loss strategies in clinical practice. Tailored approaches to GLP-1 treatment plans and support can help ensure sustainable weight loss strategies and improve patient adherence in clinical practice.